Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-12059448-B2 · Aug 13, 2024 · US
Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
US2018264072A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018264072-A1 |
| Application number | US-201615764621-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 29, 2016 |
| Priority date | Sep 29, 2015 |
| Publication date | Sep 20, 2018 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
First claim
Opening claim text (preview).
1 - 13 . (canceled) 14 . A polypeptide comprising the three following vinculin binding sites (VBS): VBS1: IYKAAKDVTTSLSKVLKNI (SEQ ID NO: 2) or a fragment or variant thereof; VBS2: IYEKAKEVSSALSKVLSKI (SEQ ID NO: 3) or a fragment or variant thereof; VBS3: IFEASKKVTNSLSNLISLI (SEQ ID NO: 4) or a fragment or variant thereof; or any sequence having at least 60% identity with SEQ ID NO: 2; 3 and 4; wherein said polypeptide is not SEQ ID NO: 1. 15 . The polypeptide according to claim 14 , wherein said polypeptide is SEQ ID NO: 5 or a variant thereof. 16 . The polypeptide according to claim 14 , being comprised in a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient. 17 . A nucleic acid comprising the three following domains: VBS1 (SEQ ID NO: 8); VBS2 (SEQ ID NO: 9); VBS3 (SEQ ID NO: 10); or any nucleic acid sequence having at least 60% identity with SEQ ID NO: 8; 9 and 10; wherein said nucleic acid is not SEQ ID NO: 7. 18 . The nucleic acid according to claim 17 , wherein said sequence is SEQ ID NO: 6. 19 . The nucleic acid according to claim 17 , being comprised in a vector. 20 . The nucleic acid according to claim 17 , being comprised in a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient. 21 . A method for treating a proliferation and/or adhesion related disease in a subject, wherein said method comprises the administration to the subject of a polypeptide comprising the three following vinculin binding sites (VBS): VBS1: IYKAAKDVTTSLSKVLKNI (SEQ ID NO: 2) or a fragment or variant thereof; VBS2: IYEKAKEVSSALSKVLSKI (SEQ ID NO: 3) or a fragment or variant thereof; VBS3: IFEASKKVTNSLSNLISLI (SEQ ID NO: 4) or a fragment or variant thereof; or any sequence having at least 60% identity with SEQ ID NO: 2; 3 and 4; wherein said polypeptide is not SEQ ID NO: 1. 22 . The method according to claim 21 , wherein said polypeptide is SEQ ID NO: 5 or a variant thereof. 23 . The method according to claim 21 , wherein said proliferation and/or adhesion related disease is a cancer. 24 . The method according to claim 21 , wherein said proliferation and/or adhesion related disease is a tumor. 25 . The method according to claim 21 , wherein said proliferation and/or adhesion related disease is metastasis. 26 . The method according to claim 21 , wherein said polypeptide is to be administered in combination with another anti-cancer agent. 27 . A method for treating a proliferation and/or adhesion related disease in a subject, wherein said method comprises the administration to the subject of a nucleic acid comprising the three following domains: VBS1 (SEQ ID NO: 8); VBS2 (SEQ ID NO: 9); VBS3 (SEQ ID NO: 10); or any nucleic acid sequence having at least 60% identity with SEQ ID NO: 8; 9 and 10; wherein said nucleic acid is not SEQ ID NO: 7. 28 . The method according to claim 27 , wherein said sequence is SEQ ID NO: 6. 29 . The method according to claim 27 , wherein said proliferation and/or adhesion related disease is a cancer. 30 . The method according to claim 27 , wherein said proliferation and/or adhesion related disease is a tumor. 31 . The method according to claim 27 , wherein said proliferation and/or adhesion related disease is metastasis. 32 . The method according to claim 27 , wherein said nucleic acid is to be administered in combination with another anti-cancer agent.
Assignees
Inventors
Classifications
- A61K38/06Primary
Tripeptides · CPC title
characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title
specific for metastasis · CPC title
Shigella (G) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2018264072A1 cover?
- Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
- Who is the assignee on this patent?
- Paris Sciences Lettres Quartier Latin, Centre Nat Rech Scient, Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification A61K38/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Sep 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).